MX341064B - Variantes de la familia il-1. - Google Patents

Variantes de la familia il-1.

Info

Publication number
MX341064B
MX341064B MX2013003877A MX2013003877A MX341064B MX 341064 B MX341064 B MX 341064B MX 2013003877 A MX2013003877 A MX 2013003877A MX 2013003877 A MX2013003877 A MX 2013003877A MX 341064 B MX341064 B MX 341064B
Authority
MX
Mexico
Prior art keywords
family variants
variants
family
lrrp2
present
Prior art date
Application number
MX2013003877A
Other languages
English (en)
Inventor
E Sims John
R Ketchem Randal
R Renshaw Blair
Gabel Christopher
E Towne Jennifer
Original Assignee
Amgen Inc *
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc * filed Critical Amgen Inc *
Publication of MX341064B publication Critical patent/MX341064B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/545—IL-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/245—IL-1
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G01N2333/545—IL-1
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/20—Screening for compounds of potential therapeutic value cell-free systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Pulmonology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Otolaryngology (AREA)
  • Transplantation (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La presente invención se refiere a un polipéptido IL-1F5 aislado que antagoniza la transducción de señal a través de IL-1Rrp2, caracterizado porque comprende la secuencia de aminoácidos que se establece en la SEQ ID NO: 8, en donde la parte N-terminal del polipéptido IL-1F5 comienza en la posición de aminoácido uno de la secuencia de aminoácidos que se establece en la SEQ ID NO: 8.
MX2013003877A 2006-09-08 2007-09-10 Variantes de la familia il-1. MX341064B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US84331106P 2006-09-08 2006-09-08
PCT/US2007/019713 WO2008033333A2 (en) 2006-09-08 2007-09-10 Il-1 family variants

Publications (1)

Publication Number Publication Date
MX341064B true MX341064B (es) 2016-08-05

Family

ID=39145963

Family Applications (3)

Application Number Title Priority Date Filing Date
MX2013003877A MX341064B (es) 2006-09-08 2007-09-10 Variantes de la familia il-1.
MX2016003106A MX373170B (es) 2006-09-08 2007-09-10 Variantes de la familia il-1.
MX2009002456A MX2009002456A (es) 2006-09-08 2007-09-10 Variantes de la familia il-1.

Family Applications After (2)

Application Number Title Priority Date Filing Date
MX2016003106A MX373170B (es) 2006-09-08 2007-09-10 Variantes de la familia il-1.
MX2009002456A MX2009002456A (es) 2006-09-08 2007-09-10 Variantes de la familia il-1.

Country Status (8)

Country Link
US (5) US8034771B2 (es)
EP (2) EP2444418A3 (es)
JP (1) JP5577543B2 (es)
AU (1) AU2007294909A1 (es)
CA (1) CA2662549C (es)
ES (1) ES2438444T3 (es)
MX (3) MX341064B (es)
WO (1) WO2008033333A2 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2011105466A (ru) * 2008-08-28 2012-10-10 ВАЙЕТ ЭлЭлСи (US) Применения цитокинов семейств il-22, il-17 и il-1 при аутоиммунных заболеваниях
FI3536710T3 (fi) * 2011-11-16 2026-01-14 Boehringer Ingelheim Int Anti-il-36r -vasta-aineita
CN107847589B (zh) 2015-04-01 2022-03-29 安奈普泰斯生物有限公司 针对t细胞免疫球蛋白和粘蛋白蛋白3(tim-3)的抗体
PL3283110T3 (pl) 2015-04-15 2022-06-27 Anaptysbio, Inc. Przeciwciała skierowane przeciwko receptorowi interleukiny 36 (il-36r)
MA51531A (fr) * 2015-07-06 2020-11-11 Immatics Biotechnologies Gmbh Nouveaux peptides et nouvelle combinaison de peptides à utiliser dans l'immunothérapie du cancer de l' oesophage et d'autres cancers
BR112019008861A2 (pt) 2016-11-01 2019-07-09 Tesaro, Inc. anticorpos direcionados contra imunoglobulina de células t e proteína de mucina 3 (tim-3)
SG10201913083SA (en) 2017-01-09 2020-03-30 Tesaro Inc Methods of treating cancer with anti-tim-3 antibodies
WO2019177888A1 (en) 2018-03-14 2019-09-19 Boehringer Ingelheim International Gmbh Use of anti-il-36r antibodies for treatment of generalized pustular psoriasis
EP3898673A1 (en) * 2018-12-21 2021-10-27 23Andme, Inc. Anti-il-36 antibodies and methods of use thereof
KR20210137520A (ko) 2019-03-08 2021-11-17 베링거 인겔하임 인터내셔날 게엠베하 항-il-36r 항체 제형
JP7812364B2 (ja) 2020-07-17 2026-02-09 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 好中球性皮膚症の処置のための抗ｉｌ－３６ｒ抗体

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
US5011912A (en) 1986-12-19 1991-04-30 Immunex Corporation Hybridoma and monoclonal antibody for use in an immunoaffinity purification system
AU643427B2 (en) 1988-10-31 1993-11-18 Immunex Corporation Interleukin-4 receptors
GB9014932D0 (en) 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
US5262522A (en) 1991-11-22 1993-11-16 Immunex Corporation Receptor for oncostatin M and leukemia inhibitory factor
JPH05244982A (ja) 1991-12-06 1993-09-24 Sumitomo Chem Co Ltd 擬人化ｂ−ｂ１０
WO1994010308A1 (en) 1992-10-23 1994-05-11 Immunex Corporation Methods of preparing soluble, oligomeric proteins
US5457035A (en) 1993-07-23 1995-10-10 Immunex Corporation Cytokine which is a ligand for OX40
AU6769298A (en) * 1997-03-21 1998-10-20 Cistron Biotechnology, Inc. Method for inhibiting cleavage of precursor il-1beta
US20020187122A1 (en) 1998-01-09 2002-12-12 Sims John E. IL-1 delta DNA and polypeptides
US6838290B2 (en) 1998-08-21 2005-01-04 Immunex Corporation Methods for screening compounds that affect IL-1 epsilon activity
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
CA2374513C (en) 1999-05-25 2009-11-24 Immunex Corporation Il-1 eta dna and polypeptides
JP2003523943A (ja) * 1999-07-16 2003-08-12 インターリューキン ジェネティックス インコーポレイテッド Ｉｌ−１ｌ１遺伝子およびポリペプチド生成物
US20060183161A1 (en) * 2000-07-17 2006-08-17 Martin Nicklin IL-ILI gene and polypeptide products

Also Published As

Publication number Publication date
US20150017123A1 (en) 2015-01-15
MX373170B (es) 2020-04-22
MX2009002456A (es) 2009-03-20
US20120020918A1 (en) 2012-01-26
JP2010502225A (ja) 2010-01-28
WO2008033333A2 (en) 2008-03-20
US20130336926A1 (en) 2013-12-19
JP5577543B2 (ja) 2014-08-27
EP2444418A2 (en) 2012-04-25
WO2008033333A3 (en) 2008-09-25
CA2662549A1 (en) 2008-03-20
EP2444418A3 (en) 2012-08-08
CA2662549C (en) 2014-10-28
US8871192B2 (en) 2014-10-28
US8481021B2 (en) 2013-07-09
EP2074139B1 (en) 2013-10-23
US8034771B2 (en) 2011-10-11
ES2438444T3 (es) 2014-01-16
US20080241096A1 (en) 2008-10-02
AU2007294909A1 (en) 2008-03-20
US20160137708A1 (en) 2016-05-19
EP2074139A2 (en) 2009-07-01

Similar Documents

Publication Publication Date Title
MX341064B (es) Variantes de la familia il-1.
EP1919302B8 (en) Food comprising silicon
SG10201405377XA (en) Compositions and methods for antibodies targeting complement protein c5
TW200637490A (en) Fertilizer-compatible composition
BR112012014082A2 (pt) composições e métodos que compreendem variantes de protease
WO2007127841A3 (en) Compositions and methods of preparation thereof
IL185380A0 (en) ANTI-MAdCAM ANTIBODY COMPOSITIONS
IL192631A (en) A drug containing an isolated antibody or a functional portion thereof, pharmaceutical preparations and a kit containing it
IL211133A (en) Preparations containing il-6 antibodies
DE602007012559D1 (de) H die schleimhaut
PL1940240T3 (pl) Kompozycje izolatu białka i ich zastosowania
WO2007082923A3 (de) Verwendung von protein-microbeads in der kosmetik
MX345909B (es) Anticuerpos anti-fgfr3 y métodos que los utilizan.
CY1113199T1 (el) Σταθεροποιημενες συνθεσεις γλυκοσερεμπροσιδασης
UA94221C2 (en) Lipocalin protein
UY3722Q (es) Estufa
BRPI0719250A2 (pt) Métodos e composições com opalescência reduzida.
TW200738751A (en) Anti-EphrinB2 antibodies and methods using same
PH12013502194A1 (en) Antibodies to egfl7 and methods for their use
ZA200800473B (en) Fuel compositions
IL227318A (en) Preparations containing enzyme for lowering immunological pressure
ZA200802308B (en) Fuel compositions
CA113787S (en) Lever
ZA200708527B (en) Use of fuel composition
PL1922128T3 (pl) Element do zmniejszania zawartości drobnego pyłu w powietrzu, za pomocą mchów i/lub porostów